| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CoVF | cobra venom factor |
|---|---|
| CVF | cardiovascular failure; central visual field; cervicovaginal fluid; cobra venom factor |
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| LyNeF | lytic nephritic factor |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| CVF | Cobra Venom Factor |
|---|---|
| CoF | Cobra venom factor |
| CoVF | Cobra venom factor |
| TLF | Trypanosome Lytic Factor |
| LU | Lytic Units |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| direct lytic factor of cobra venom | A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent. Synonym: cobra toxin, direct lytic factor of cobra venom. (05 Mar 2000) |
|---|
| cobra venom factor | A component of cobra venom that renders C3 proactivator (properdin factor B) susceptible to factor D of the properdin system, leading to activation of C3 and other components of complement and lysis of unsensitised erythrocytes. (05 Mar 2000) |
|---|---|
| cobra venom cofactor | <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase. Registry number: EC 3.4.21.47 (12 Dec 1998) |
| direct lytic factors | most abundant proteins in cobra (naja of the elapids) venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contracture, interferes with neuromuscular and ganglionic transmission, depolarises nerve, muscle and blood cell membranes, thus causing haemolysis. Synonym: cobramine a; cobramine b; cobra cytotoxin; gamma toxin; membrane-active polypeptide. (12 Dec 1998) |
| cobra | A genus of poisonous snakes of the subfamily elapinae of the family elapidae. There are six recognised species, all inhabiting africa except the asiatic (indian) cobra, naja naja. Some species "spit" their venom into the eyes of their "enemies". So-called spitting cobras show a high degree of accuracy in aiming for the eyes. The ringhals, the most highly specialised of the spitting cobras, is limited to southern africa. Its spray destroys eye tissue and can cause blindness; its bite can cause death. (moore: poisonous snakes of the world, 1980, p80) (12 Dec 1998) |
| cobra neurotoxins | Toxins, contained in cobra (naja) venom that block cholinergic receptors; two specific proteins have been described, the small (short, type I) and the large (long, type II) which also exist in other elapid venoms. (12 Dec 1998) |
| cobra toxin | A polypeptide of 62 residues; action on cells is similar to that of melittin in that it promotes disruption of membranes; used as an investigational antirheumatic agent. Synonym: cobra toxin, direct lytic factor of cobra venom. (05 Mar 2000) |
| cobra venoms | Venoms from snakes of the genus naja (family elapidae). They contain many specific proteins that have cytotoxic, haemolytic, neurotoxic, and other properties. Like other elapid venoms, they are rich in enzymes. They include cobramines and cobralysins. (12 Dec 1998) |
| black widow spider venom | Potent neurotoxin that induces catastrophic release of acetylcholine from presynaptic terminals of cholinergic chemical synapses. (18 Nov 1997) |
| venom | <chemical> A toxic secretion in animals that is actively delivered to the target organism, either to paralyse or incapacitate or else to cause pain as a defence mechanism. Commonly include protein and peptide toxins. (12 Jan 1998) |
| venom haemolysis | That caused by haemolytic material in the venom of various species of snakes or other venomous animals. (05 Mar 2000) |
| Russell's viper venom | A venom used as a coagulant in the arrest of haemorrhage from accessible sites in haemophilia. (05 Mar 2000) |
| Russell's viper venom clotting time | A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects. See: Stypven time test. (05 Mar 2000) |
| crotalid venom | <herpetology> Venoms from snakes of the subfamily crotalinae or pit vipers, found mostly in the americas. They include the rattlesnake, cottonmouth, fer-de-lance, bushmaster, and american copperhead. Their venoms contain nontoxic proteins, cardio-, haemo-, cyto-, and neurotoxins, and many enzymes, especially phospholipases a. Many of the toxins have been characterised. (12 Dec 1998) |
| kokoi venom | A potent neurotoxin found in the frog Phyllobates bicolor; it is a nonprotein compound with a molecular weight of approximately 400, and is lethal in microgram quantities. (05 Mar 2000) |
| Mlt38 lytic transglycosylase | <enzyme> Active against poly(murnac-glcnac) strands Registry number: EC 2.4.- Synonym: membrane-bound lytic transglycosylase 38-kD, mlt38 protein, mlta gene product (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|